RxDoctor Payments Data

Connie Chen, MD

Family Medicine · Oceanside, CANPI 1851319693

Payments from drug & device makers

$502in general payments, 2019–2025

Across 9 payments — averaging $55.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$114
  • Corcept Therapeutics$104
  • TMS Neurohealth Centers Inc.$98
  • Novo Nordisk$54
  • Intra-sana Laboratories$50
  • Abbott$49
  • plus $32 from 1 others

What the payments were for

  • Food & beverage$502100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$114
Corcept Therapeutics1$104
TMS Neurohealth Centers Inc.1$98
Novo Nordisk3$54
Intra-sana Laboratories1$50
Abbott1$49
Merck1$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$502 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$169,544
Medicare patients
242
Services billed
2,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$113,885
EliquisApixaban54$91,625
ProliaDenosumab28$44,554
JanuviaSitagliptin Phosphate25$35,149
RybelsusSemaglutide16$33,722
JardianceEmpagliflozin15$26,167
FarxigaDapagliflozin Propanediol15$24,947
TrulicityDulaglutide12$19,051
XareltoRivaroxaban25$18,758
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,699
Rosuvastatin Calcium181$5,634
Breo ElliptaFluticasone/Vilanterol13$5,042
Atorvastatin Calcium485$4,337
Memantine Hcl ErMemantine Hcl11$3,828
Losartan Potassium315$2,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$54$147,60688 claims
MerckJanuvia$32$35,14925 claims
AstraZenecaFarxiga$114$24,94715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Oceanside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →